Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.54 |
| ▸ | HTR2B | P41595 | 15/20 | 0.54 |
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627752 | 0.91 | HTR2C (0.57) | HTR2CHTR2BHTR6HTR2AHTR1A | |
| SCHEMBL697549 | 0.91 | HTR2C (0.61) | HTR2CHTR2BHTR6HTR2A | |
| SCHEMBL2018076 | 0.91 | HTR2C (0.61) | HTR2CHTR2BHTR6HTR2A | |
| SCHEMBL2018056 | 0.90 | HTR2C (0.51) | HTR2CHTR2BHTR6HTR2AHTR1A | |
| SCHEMBL2019854 | 0.87 | HTR2C (0.44) | HTR2CHTR2BHTR6HTR2A | |
| SCHEMBL2576587 | 0.86 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL2013664 | 0.86 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL2572284 | 0.85 | HTR2C (0.51) | HTR2CHTR2BHTR6HTR2AHTR1A | |
| SCHEMBL2020219 | 0.85 | HTR2C (0.51) | HTR2CHTR2BHTR6HTR2AHTR1A | |
| SCHEMBL2020139 | 0.85 | HTR2C (0.41) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | claimed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | claimed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | HTR2C 8/4885HTR2B 11/4885HTR6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.